Natalizumab for Achieving Relapse-Free, T1 Gadolinium-Enhancing-Lesion-Free, and T2 Lesion-Free Status in Japanese Multiple Sclerosis Patients: A Phase 2 Trial Subanalysis

INTRODUCTION: In a phase 2 trial of natalizumab in Japanese patients with relapsing-remitting multiple sclerosis (RRMS), treatment-related changes in relapses, brain lesions, and disability worsening were found to be comparable with those observed in the phase 3 studies of natalizumab in primarily n...

Descripción completa

Detalles Bibliográficos
Autores principales: Saida, Takahiko, Kira, Jun-Ichi, Kishida, Shuji, Yamamura, Takashi, Ohtsuka, Nobuhisa, Dong, Qunming, Tibung, J. T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447555/
https://www.ncbi.nlm.nih.gov/pubmed/28078634
http://dx.doi.org/10.1007/s40120-016-0062-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447555/
https://www.ncbi.nlm.nih.gov/pubmed/28078634
http://dx.doi.org/10.1007/s40120-016-0062-4

Ejemplares similares